Education
About Us
Working with TipRanks
Follow Us
BeOne Medicines Ltd (HK:6160)
:6160
Total Valuation
BeOne Medicines Ltd has a market cap or net worth of HK$347.98B. The enterprise value is HK$36.35B.
Market CapHK$347.98B
Enterprise ValueHK$36.35B
Share Statistics
BeOne Medicines Ltd has 1,540,976,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,540,976,000
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
BeOne Medicines Ltd’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -12.42%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-12.42%
Return on Capital Employed (ROCE)-0.15
Revenue Per Employee346.39K
Profits Per Employee-58.62K
Employee Count11,000
Asset Turnover0.64
Inventory Turnover1.20
Valuation Ratios
The current PE Ratio of BeOne Medicines Ltd is 688.1. BeOne Medicines Ltd’s PEG ratio is 1.08.
PE Ratio688.1
PS Ratio5.05
PB Ratio5.77
Price to Fair Value5.77
Price to FCF-28.72
Price to Operating Cash Flow47.24
PEG Ratio1.08
Income Statement
In the last 12 months, BeOne Medicines Ltd had revenue of 3.81B and earned -644.79M in profits. Earnings per share was -0.47.
Revenue3.81B
Gross Profit3.22B
Operating Income-568.20M
Pretax Income-533.00M
Net Income-644.79M
EBITDA-396.44M
Earnings Per Share (EPS)-0.47
Cash Flow
In the last 12 months, operating cash flow was 785.39M and capital expenditures -321.49M, giving a free cash flow of 463.90M billion.
Operating Cash Flow785.39M
Free Cash Flow463.90M
Free Cash Flow per Share0.30
Dividends & Yields
BeOne Medicines Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.03
52-Week Price Change32.43%
50-Day Moving Average199.23
200-Day Moving Average184.36
Relative Strength Index (RSI)57.39
Average Volume (3m)5.08M
Important Dates
BeOne Medicines Ltd upcoming earnings date is Apr 30, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
BeOne Medicines Ltd as a current ratio of 1.80, with Debt / Equity ratio of 24.70%
Current Ratio1.80
Quick Ratio1.58
Debt to Market Cap0.05
Net Debt to EBITDA3.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BeOne Medicines Ltd has paid 111.78M in taxes.
Income Tax111.78M
Effective Tax Rate-0.21
Enterprise Valuation
BeOne Medicines Ltd EV to EBITDA ratio is -44.61, with an EV/FCF ratio of -26.41.
EV to Sales4.64
EV to EBITDA-44.61
EV to Free Cash Flow-26.41
EV to Operating Cash Flow-125.76
Balance Sheet
BeOne Medicines Ltd has HK$4.04B in cash and marketable securities with HK$1.02B in debt, giving a net cash position of HK$3.02B billion.
Cash & Marketable SecuritiesHK$4.04B
Total DebtHK$1.02B
Net CashHK$3.02B
Net Cash Per ShareHK$1.96
Tangible Book Value Per ShareHK$2.34
Margins
Gross margin is 86.19%, with operating margin of -14.91%, and net profit margin of -16.92%.
Gross Margin86.19%
Operating Margin-14.91%
Pretax Margin-13.99%
Net Profit Margin-16.92%
EBITDA Margin-10.40%
EBIT Margin-14.91%
Analyst Forecast
The average price target for BeOne Medicines Ltd is HK$255.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$255.33
Price Target Upside19.31% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast49.63%
EPS Growth Forecast―